Application of Telemedicine to the Management of Aggressive Lymphomas

University Hospital, Toulouse350 enrolled

Overview

The purpose of this study is to evaluate the value of AMA in a comparative multicenter regional study as a reference for aggressive lymphoma. The primary endpoint will be RDI. This study consider that the AMA support should allow a significant improvement of the RDI compared to the control group and thus impact the duration without progression. The study covers 350 patients recruited from 10 regional centers.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

350

Conditions

Lymphoma

Interventions

AMA (Assistance for ambulatory patients)OTHER

telephone follow-up modality

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient with a recent diffuse large B cell lymphoma (LBDGC), histologically proven, with treatment not started * a priori likely to be treated by rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone every 21 days (R-CHOP21) for 8 cycles or rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (R-ACVBP). * Index international prognosis (IPI) measurable (IPI-aa), adjusted for age. Any IPI-aa is eligible. * accepting the study Exclusion Criteria: * Patient with another type of lymphoma (including transformed follicular forms) * Patient having already started his treatment. * Life expectancy \<3 months. * Carcinologic history * Serum positive for HIV or hepatitis B virus (HBV).

Locations (10)

University Hospital of Toulouse

Toulouse, France, France

Clinique Claude Bernard

Albi, France

Hospital

Auch, France

Bayonne Hospital

Bayonne, France

Outcomes

Primary Outcomes

dose-relative intensity (RDI)

reduction of RDI

Time frame: through study completion, an average of 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.